Additional Information

Pinar Cakilkaya is pursuing her doctoral degree from University of Copenhagen. She is interested in developing antibody drug conjugates (ADCs) for treating mesothelioma. She has developed anti-uPARAP ADC, and is testing it on mouse mesothelioma models. Pinar is developing uPARAP-targeted CAR-T cells as a novel immunotherapy for mesothelioma patients.